Induced Abortion Guidelines

Journal of Obstetrics and Gynaecology Canada

Volumn 28, Issue 11, 2006, Pages 1014-1027

  Davis, Victoria Jane ^a  

^a NONE

Author keywords

[No Author keywords available]

Indexed keywords

ANTIBIOTIC AGENT; ANTIEMETIC AGENT; CARBOPROST; CHORIONIC GONADOTROPIN BETA SUBUNIT; DILAPAN; FENTANYL; LIDOCAINE; METHOTREXATE; METRONIDAZOLE; MIDAZOLAM; MISOPROSTOL; NONSTEROID ANTIINFLAMMATORY AGENT; OXYTOCIN; PLACEBO; PROSTAGLANDIN F2 ALPHA; RHESUS ANTIGEN; RHESUS D ANTIBODY; VASOPRESSIN;

ALLERGIC REACTION; AMNIOCENTESIS; ANTIBIOTIC PROPHYLAXIS; ARTICLE; BLEEDING; CONSCIOUS SEDATION; DIARRHEA; DILATION AND EVACUATION; DRUG DOSE COMPARISON; ENDOMETRIOSIS; FIRST TRIMESTER PREGNANCY; GASTROINTESTINAL SYMPTOM; GYNECOLOGIST; HEMATOMETRA; HUMAN; HYSTERECTOMY; HYSTEROTOMY; INCOMPLETE ABORTION; INDUCED ABORTION; INFECTION; INFORMED CONSENT; LABOR INDUCTION; MEDICAL ABORTION; NAUSEA; PAIN; PARACERVICAL BLOCK; PATIENT COUNSELING; PATIENT SELECTION; PELVIC INFLAMMATORY DISEASE; PHYSICAL EXAMINATION; POSTOPERATIVE CARE; PRACTICE GUIDELINE; PREGNANCY TERMINATION; RECOMMENDED DRUG DOSE; SECOND TRIMESTER PREGNANCY; SEXUALLY TRANSMITTED DISEASE; SICKLE CELL ANEMIA; SURGICAL ABORTION; UTERINE CERVIX CYTOLOGY; UTERINE CERVIX DILATATION; UTERINE CERVIX RIPENING; UTERUS PERFORATION; UTERUS RUPTURE; VACUUM ASPIRATION; VAGINITIS;

EID: 84971467509     PISSN: 17012163     EISSN: None     Source Type: Journal    
DOI: 10.1016/S1701-2163(16)32296-4     Document Type: Article

References (86)

1. Rosenfield A. Abortion and women's reproductive health. Int J Gynaecol Obstet 1994, 46:173-179.
2. Cates W., Grimes D.A. Deaths from second trimester abortion by dilation and evacuation: causes, prevention, facilities. Obstet Gynecol 1981, 58:401-408.
3. Grimes D.A., Cates W., Selik R.M. Abortion facilities and the risk of death. Fam Plann Perspect 1981, 13:30-32.
4. Henshaw S.K. Factors hindering access to abortion services. Fam Plann Perspect 1995, 27:54-59.
5. Statistics Canada. Induced (Therapeutic) Abortion 2000 2000, Health Statistics Division, Ottawa, Available at:, Accessed: July 10, 2006. http://www.statcan.ca/.
6. Davis V.J., Mykitiuk R. The rights of the adolescent: the mature minor. J Soc Obstet Gynaecol Can 2001, 23(4):343-345.
7. Larsson P.G., Platz-Christensen J.J., Thejls H., Forsum U., Pahlson C. Incidence of pelvic inflammatory disease after first-trimester legal abortion in women with bacterial vaginosis: a double-blind randomized study. Am J Obstet Gynecol 1992, 166:100-103.
8. Wiebe E.R. Abortion induced with methotrexate and misoprostol. Can Med Assoc J 1996, 154:165-170.
9. Cameron S.T., Glassier A.F., Logan J., Benton L., Baird D.T. Impact of the introduction of new medical methods on therapeutic abortions at the Royal Infirmary of Edinburgh. Br J Obstet Gynaecol 1996, 103:1222-1229.
10. Blayo C. L'evolution du recours a l'avortement en France depuis 1976. Population 1995, 779-810.
11. Creinin M.D., Darney P.D. Methotrexate and misoprostol for early abortion. Contraception 1993, 48:339-348.
12. Creinin M.D., Vittinghoff E., Keder L., Darney P.D., Tiller G. Methotrexate and misoprostol for early abortion: a multicenter trial. I. Safety and efficacy. Contraception 1996, 53:321-327.
13. Creinin M.D. Oral methotrexate and vaginal misoprostol for early abortion. Contraception 1996, 54:15-18.
14. Creinin M.D., Vittinghoff E., Schaff E., Klaisle C., Darney P.D., Dean C. Medical abortion with oral methotrexate and vaginal misoprostol. Obstet Gynecol 1997, 90:611-616.
15. Gonzalez C.H., Vargus R., Perez A.B., Kim C.A., Brunoni D., Marques-Dias M.J. Limb deficiency with or without Mobius sequence in seven Brazilian children associated with misoprostol use in the first trimester. Am J Med Genet 1993, 47:59-64.
16. Pastuszak A.L., Schuler L., Speck-Martins C.E., Coelho K.E., Cordello S.M., Vargas F. Use of misoprostol during pregnancy and Mobius sequence in infants. N EnglJ Med 1998, 338:1881-1885.
17. Kozlowski R.D., Steinbrunner J.V., MacKenzie A.H., Clough J.D., Wilke W.S., Segal A.M. Outcome of first trimester exposure to low-dose methotrexate in eight patients with rheumatic disease. Am J Med 1990, 88:589-592.
18. Carbonell J.L.L., Varela L., Velazco A., Fernandez C. The use of misoprostol for the termination of early pregnancy. Contraception 1997, 55:165-168.
19. Ngai S.W., Tang O.S., Chan Y.M., Ho P.C. Vaginal misoprostol alone for medical abortion up to 9 weeks of gestation: efficacy and acceptability. Hum Reprod 2000, 15:2205-2208.
20. Bugalho A., Faundes A., Jamisse L., Usfa M., Maria E., Bique C. Evaluation of vaginal misoprostol to induce first trimester abortion. Contraception 1996, 53:243-246.
21. Borgatta L., Chen A., Mullaly B., Stubblefield P.G. Early medical abortion using misoprostol alone in a low income setting. Obstet Gynecol 2003, 101:14.
22. Hausknecht R.U. Methotrexate and misoprostol to terminate early pregnancy. N Eng J Med 1995, 333:537-540.
23. Grimes D. Medical abortion in early pregnancy: a review of evidence. Obstet Gynecol 1997, 89:790-796.
24. Schaff E.A., Wortman M., Eisinger S., Franks P. Methotrexate and misoprostol when surgical abortion fails. Obstet Gynecol 1996, 87:450-452.
25. Davis V.J. Guidelines for medical termination of pregnancy. J Soc Obstet Gynaecol Can 1999, 21(12):1169-1174.
26. Lichtenberg E.S., Paul M., Jones H. First trimester surgical abortion practices: a survey of National Abortion Federation members. Contraception 2001, 64:345-352.
27. Creinin M.D., Edwards J. Early abortion: surgical and medical options. Curr Probl Obstet Gynecol Fertil 1997, 20:1-32.
28. Hodgson J.E. A reassessment of menstrual regulation. Stud Fam Plann 1977, 8(10):263-267.
29. Goldberg A.B., Dean G., Kang M.S., Youssof S., Darney P.D. Manual versus electric vacuum aspiration for early first-trimester abortion: a controlled study of complication rates. Obstet Gynecol 2004, 103:101.
30. Grimes D.A., Schulz K.F., Cates W., Tyler W. Local versus general anesthesia: which is safer for performing suction curettage abortions?. Am J Obstet Gynecol 1979, 135(8):1030-1035.
31. Castadot R.G. Pregnancy termination: techniques, risks and complications and their management. Fertil Steril 1986, 45(1):5-17.
32. Hern W.M. Laminaria in abortion: use in 1368 patients in first trimester abortio. Rocky MT Med J 1975, 72(9):390-395.
33. Newton B.W. Laminaria osmotic dilator: relic of the past or modern medical device?. Am J Obstet Gynecol 1979, 113(4):442-448.
34. El-Refaey H., Calder L., Wheatley, Templeton A. Cervical priming with prostaglandin E1 analogues, misoprostol and gemeprost. Lancet 1994, 343:1207-1209.
35. Goldberg A.B., Greenberg M.B., Darney P.D. Drug therapy: misoprostol and pregnancy. N Engl J Med 2001, 344:38-45.
36. Ngai S.W., Tang O.S., Lao T., Ho P.C., Ma H.K. Oral misoprostol versus placebo for cervical dilatation prior to vacuum aspiration in first trimester pregnancy. Hum Reprod 1995, 10:1220-1222.
37. Schultz K.F., Grimes D.A., Cates W. Measures to prevent cervical injury during suction curettage abortion. Lancet 1983, 1:1182-1184.
38. Grimes D.A., Schultz K.F., Cates W. Prevention of uterine perforation during curettage abortion. JAMA 1984, 251:2108-2111.
39. Durack D.T. Prevention of infective endocarditis. N Engl J Med 1995, 332:38-44.
40. Sawaya G.F., Grady D., Kerlikowske K., Grimes D.A. Antibiotics at the time of induced abortion: the case for universal prophylaxis based on a meta-analysis. Obstet Gynecol 1996, 87:884-890.
41. Jones J.L., Kaunitz A.M. Medical screening. Clinical training curriculum in abortion practice 1995, National Abortion Federation, Washington, DC. M.J. Policar, A.E. Pollack (Eds.).
42. Grimes D.A., Schulz K.F., Cates W. Prophylactic antibiotics for curettage abortion. Am J Obstet Gynecol 1984, 150:689-694.
43. Lichtenberg E.S., Paul M.E., Saporta V. 1997 Provider clinical survey: first trimester surgical abortion practice 1997, National Abortion Federation, Washington, DC.
44. Smith G.M., Stubblefield P.G., Chirchirillo L., McCarthy M.J. Pain of first trimester abortion: its quantification and relations with other variables. Am J Obstet Gynecol 1979, 133:489-498.
45. Suprapto K., Reed S. Naproxen sodium for pain relief in first-trimester abortion. Am J Obstet Gynecol 1984, 150:1000-1001.
46. Keder L.M. Best practices in surgical abortion. Am J Obstet Gynecol 2003, 189:418-422.
47. Wong C.Y., Ng E.H., Ngai S.W., Ho P.C. A randomized, double blind, placebo-controlled study to investigate the use of conscious sedation in conjunction with paracervical block for reducing pain in termination of first trimester pregnancy by suction evacuation. Hum Reprod 2002, 17:1222-1225.
48. Rawling M.J., Wiebe E.R. A randomized controlled trial of fentanyl for abortion pain. Am J Obstet Gynecol 2001, 185:103-107.
49. Schultz K.F., Grimes D.A., Christensen D.D. Vasopressin reduces blood loss from second-trimester dilatation and evacuation abortion. Lancet 1985, 2:353-356.
50. Penfield A.J. Gynecologic surgery under local anaesthesia. Gynecologic surgery under local anaesthesia 1986, 48-49. Urban and Schwarzenberg, Baltimore-Munich. A.J. Penfield (Ed.).
51. Hodgson J.E. Abortion by vacuum aspiration. Abortion and sterilization: medical and social aspects 1981, 225. Grune and Strattion, New York. J.E. Hodgson (Ed.).
52. Laurensen N.H., Conrad P. Effect of oxytocin agents on blood loss during first trimester suction curettage. Obstet Gynecol 1974, 44:428-433.
53. Munsick R.A. Clinical test for placenta in 100 consecutive menstrual aspirations. Obstet Gynecol 1982, 60:738-741.
54. Stubblefield P.G., Berek J.S. Anatomical and clinical correlations of uterine perforations. Am J Obstet Gynecol 1979, 135:181-184.
55. Lindell G., Flam F. Management of uterine perforations in connection to legal abortions. Acta Obstet Gynecol 1995, 74:373-375.
56. Borgatta L., Chen A.Y., Reid S.K., Stubblefield P.G., Christensen D.D., Rashbaum W.K. Pelvic embolization for treatment of hemorrhage related to spontaneous and induced abortion. Am J Obstet Gynecol 2001, 185:530-536.
57. Stubblefield P.G., Borgatta L. Complications after induced abortion. Emergency care of the woman: diagnosis and management 1985, 65-86. McGraw Hil, New Yorkl. M.D. Pearlman, J.E. Tintinalli, P.L. Dyne (Eds.).
58. Grimes D.A., Schulz K.F. Morbidity and mortality from second trimester abortion. J Reprod Med 1985, 30(7):505-514.
59. Hern W.H. Second trimester surgical abortion. Gynecology and obstetrics 2003, 6:1-16. Lippincott, Williams and Wilkins, Philadelphia. J.J. Sciarra (Ed.).
60. Schneider D., Halperin R., Langer R., Caspi E., Bukovsky I. Abortion at 18-22 weeks by laminaria dilatation and evacuation. Obstet Gynecol 1996, 88:412-414.
61. Todd C.S., Soler M., Castleman M., Rogers M.K., Blumenthal P.D. Buccal misoprostol as a cervical preparation for second trimester pregnancy termination. Contraception 2002, 65:415-418.
62. Stubblefield P.G., Naftolin F., Frigoletto F., Ryan K.J. Laminaria augmentation of intra-amniotic PGF" for midtrimester pregnancy termination. Prostaglandins 1975, 10:413-422.
63. Toppozada M.K., Shaala S.A., Anwar M.Y., Haiba N.A., Abdrabbo S., el-Absy H.M. Termination of pregnancy with fetal death in the second and third trimesters-the double balloon versus extra-amniotic prostaglandin. Int J Gynaecol Obstet 1994, 45:269-273.
64. Stubblefield P.G., Carr-Ellis S., Borgatta L. Methods of induced abortion. Obstet Gynecol 2004, 104:174-185.
65. The Society of Obstetricians and Gynaecologists of Canada Induced abortion guidelines. J Soc Obstet Gynaecol Can 1996, 48:1-18.
66. Ferguson J.E., Burkett B.J., Pinkerton J.V., Thiagarajah S., Flather M.M., Martel M.M. Intraamniotic 15(s)-15-methyl prostaglandin F2 alpha and termination of middle and late second-trimester pregnancy for genetic indications: a contemporary approach. Am J Obstet Gynecol 1993, 169:332-339.
67. Burkman R.T., Atienza M.F., King T.M., Tonascia J.A., Tonascia J.A., Pang J.C., et al. Hyperosmolar urea for elective midtrimester abortion. Am J Obstet Gynecol 1978, 131(1):1-7.
68. Peat B. Second trimester abortion by extra-amniotic PGF2 alpha infusion: experience of 178 cases. Aust NZ J Obstet Gynaecol 1991, 31(1):47-51.
69. Hill N.C., Mackenzie I.Z. 2308 second trimester terminations using extra-amniotic or intra-amniotic prostaglandins E2: analysis of efficacy and complications. Br J Obstet Gynaecol 1989, 96(12):1424-1431.
70. Corson S.L., Bolognese R.J. Use of intramuscular 15(S)-15-methyl prostaglandin F2 alpha in failed abortion. Am J Obstet Gynecol 1989, 133(2):47-51.
71. Osler M., Lange A.P., Moth I., Thomsen-Pedersen G., Westergaard J.G. 15(S)-15-methyl prostaglandin F2 alpha used for induction of delivery in the case of intra-uterine fetal death. Acta Obstet Gynecol Scand 1985, 64(2):131-132.
72. Antsaklis A., Politis J., Diacomanolis E., Aravantino D., Kaskarelis D. The use of 15-methylated derivative of prostaglandin F2a for the therapeutic termination of pregnancy and management of fetal death. Int Surg 1984, 69(1):63-68.
73. Hayashi R.H., Catillo M.S., Noah M.L. Management of severe post-partum hemorrhage with prostaglandins F2 alpha analogue. Obstet Gynecol 1984, 63(6):806-808.
74. Winkler C.L., Gray S.E., Hauth J.C., Owen J., Tucker J.M. Mid-second trimester labor abortion induction: concentrated oxytocin compared with prostaglandin E2 vaginal suppositories. Obstet Gynecol 1991, 77(2):297-300.
75. Chittacharoen A., Herabutya Y., Punyavachira P. A ramdomized trial of oral and vaginal misoprostol to manage delivery in case of fetal death. Obstet Gynecol 2003, 101:1353-1354.
76. Herabutya Y., O-Prasertsawat P. Second trimester abortion using intravaginal misoprostol for termination of second trimester pregnancy. Int J Gynaecol Obstet 1998, 60:161-165.
77. Jain J.K., Mishell D.R. A comparison of intravaginal misoprostol with prostaglandin E2 for termination of second trimester pregnancy. N Engl J Med 1994, 331:290-293.
78. Jain J.K., Kuo J., Mishell D.R. A comparison of two dosing regimens of intravaginal misoprostol for second trimester pregnancy termination. Obstet Gynecol 1999, 93:571-575.
79. Jain J.K., Mishell D.R. A comparison of misoprostol with and without laminaria tents for induction of second trimester abortion. Am J Obstet Gynecol 1996, 175:173-177.
80. Grimes D.A., Hulka J.F., McCutchen M.E. Mid-trimester abortion by dilatation and evacuation versus intra-amniotic instillation of prostaglandin F2a: a randomized clinical trial clinical trial. Am J Obstet Gynecol 1980, 137:785-790.
81. Kafrissen M.E., Schulz K.F., Grimes D.A., Cates W. Midtrimester abortion: intra-amniotic instillation of hyperosmolar urea and prostaglandin F2a v dilatation and evacuation. JAMA 1984, 251:916-919.
82. Autry A.M., Hayes E.C., Jacobson G.F., Kirby R.S. A comparison of medical induction and dilatation and evacuation for second-trimester abortion. Am J Obstet Gynecol 2002, 187:393-397.
83. MacKay H.T., Schulz K.F., Grimes D.A. Safety of local versus general anesthesia for second trimester dilatation and evacuation abortion. Obstet Gynecol 1985, 66:661-665.
84. Kaunitz A.M., Rovira E.Z., Grimes D.A., Shulz K.F. Abortions that fail. Obstet Gynecol 1985, 66(4):33-37.
85. Black A., Francoeur D., Rowe T., Collins J., Miller D., Brown T., et al. Canadian Contraception Consensus. SOGC Clinical Practice Guidelines, No.143-part 1, February 2004. J Obstet Gynaecol Can 2004, 26(2):143-156.
86. Woolf S.H., Battista R.N., Angerson G.M., Logan A.G., Eel W. Canadian Task Force on the Periodic Health Exam 1994, xxxvii. Canada Communication Group, Ottawa.